JP2024511281A - 抗ｃｌｄｎ１８．２抗体コンジュゲート - Google Patents

抗ｃｌｄｎ１８．２抗体コンジュゲート Download PDF

Info

Publication number
JP2024511281A
JP2024511281A JP2023550307A JP2023550307A JP2024511281A JP 2024511281 A JP2024511281 A JP 2024511281A JP 2023550307 A JP2023550307 A JP 2023550307A JP 2023550307 A JP2023550307 A JP 2023550307A JP 2024511281 A JP2024511281 A JP 2024511281A
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023550307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511281A5 (https=
Inventor
キアン，シュエミン
チュー，フア
テン，フェイ
リー，ホンジュン
ヤン，ジー
グー，イー
ディン，ジン
ワン，フェン
Original Assignee
スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド
ベイジン・キャンサー・ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド, ベイジン・キャンサー・ホスピタル filed Critical スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド
Publication of JP2024511281A publication Critical patent/JP2024511281A/ja
Publication of JP2024511281A5 publication Critical patent/JP2024511281A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023550307A 2021-02-19 2022-02-18 抗ｃｌｄｎ１８．２抗体コンジュゲート Pending JP2024511281A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/076910 2021-02-19
CN2021076910 2021-02-19
CN2022074750 2022-01-28
CNPCT/CN2022/074750 2022-01-28
PCT/CN2022/076810 WO2022174809A1 (en) 2021-02-19 2022-02-18 Anti-cldn18.2 antibody conjugates

Publications (2)

Publication Number Publication Date
JP2024511281A true JP2024511281A (ja) 2024-03-13
JP2024511281A5 JP2024511281A5 (https=) 2025-02-27

Family

ID=82932096

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023550307A Pending JP2024511281A (ja) 2021-02-19 2022-02-18 抗ｃｌｄｎ１８．２抗体コンジュゲート

Country Status (9)

Country Link
US (1) US20240307564A1 (https=)
EP (1) EP4294441A4 (https=)
JP (1) JP2024511281A (https=)
KR (1) KR20230146623A (https=)
CN (1) CN117460528A (https=)
AU (1) AU2022223150A1 (https=)
CA (1) CA3211403A1 (https=)
TW (1) TW202302153A (https=)
WO (1) WO2022174809A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024041574A1 (en) * 2022-08-24 2024-02-29 Suzhou Transcenta Therapeutics Co., Ltd. Non-invasive methods using anti-cldn18.2 antibody-radionuclide conjugates
KR20240176948A (ko) * 2023-06-15 2024-12-26 에이비온 주식회사 소세포폐암 진단 및 치료를 위한 타겟으로서 클라우딘-3의 용도
KR20250062080A (ko) 2023-10-30 2025-05-08 주식회사 엘지에너지솔루션 배터리 데이터 수집 서버 및 이의 동작 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111777681A (zh) * 2020-07-06 2020-10-16 上海岺樾生物医药科技有限公司 一种结合紧密连接蛋白-18.2的抗体及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2852409B1 (en) * 2012-05-23 2020-03-25 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
EP3765522A4 (en) * 2018-03-14 2022-05-18 Beijing Xuanyi Pharmasciences Co., Ltd. ANTI-CLAUDIN 18.2 ANTIBODIES
WO2019242505A1 (zh) * 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
WO2020025792A1 (en) * 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Antibody constructs for cldn18.2 and cd3
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN114206935B (zh) * 2019-05-24 2024-01-12 三优生物医药(上海)有限公司 新型cldn18.2结合分子
JP7767270B2 (ja) * 2019-08-20 2025-11-11 スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド 新規抗ｃｌｄｎ１８．２抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111777681A (zh) * 2020-07-06 2020-10-16 上海岺樾生物医药科技有限公司 一种结合紧密连接蛋白-18.2的抗体及其用途

Also Published As

Publication number Publication date
CN117460528A (zh) 2024-01-26
KR20230146623A (ko) 2023-10-19
US20240307564A1 (en) 2024-09-19
AU2022223150A9 (en) 2024-01-04
WO2022174809A1 (en) 2022-08-25
TW202302153A (zh) 2023-01-16
AU2022223150A1 (en) 2023-09-21
EP4294441A1 (en) 2023-12-27
CA3211403A1 (en) 2022-08-25
EP4294441A4 (en) 2026-03-25

Similar Documents

Publication Publication Date Title
JP5919604B2 (ja) 抗膵癌抗体
JP6970017B2 (ja) ヒトａ３３抗原とｄｏｔａ金属複合体に親和性を有する多重特異性抗体及びその使用
KR101820029B1 (ko) 암의 예방 및/또는 치료에서 사용하기 위한 방사성 표지 항체 단편
MD3548515T2 (ro) Anticorpi anti-PD-L1 radiomarcați pentru imagistica imuno-PET
KR20220057517A (ko) 신생아 fc 수용체에 대한 감소된 친화성을 갖는 psma 결합을 위한 항체
US20250073359A1 (en) Radiolabeled biomolecules and their use
TR201901824T4 (tr) Rs7 Antikorları
US20240307564A1 (en) Anti-cldn18.2 antibody conjugates
US20230340111A1 (en) Antibody fragment against folr1
US12605473B2 (en) Methods for making radiolabeled anti-MET binding proteins
WO2024041574A1 (en) Non-invasive methods using anti-cldn18.2 antibody-radionuclide conjugates
US20240124595A1 (en) Antibodies to igf2r and methods
JP2024505963A (ja) 抗ｏｘＭＩＦ放射性免疫コンジュゲート
HK40106087A (zh) 抗cldn18.2抗体缀合物
US20250340662A1 (en) Binding protein
EA052523B1 (ru) Антитела против cd44v6 и их использование для лечения онкологических заболеваний, характеризующихся гиперэкспрессией cd44v6
TW202607033A (zh) 抗ｒｏｒ２抗體－放射性核種結合物
WO2025035107A2 (en) Trophoblast glycoprotein antibody compositions and methods of use
WO2025207904A1 (en) Psma radiopharmaceutical conjugate and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260204